According to a report, artificial intelligence (AI) is not only capable of producing numerous essays and passing bar examinations, but it can even diagnose and treat various cancers.
In just 30 days, scientists from the University of Toronto and Insilico Medicine created a medication that could treat hepatocellular carcinoma (HCC), or liver cancer. They did this by using an AI database called AlphaFold.
They made an even stronger hit molecule in the second round, but the researchers insisted that further clinical testing is still required before the medicine can be used to treat cancer in hospitals.
But they added that before a medicine could be used to treat cancer, it would still need to go through clinical studies.
The AI-powered AlphaFold, according to the study’s co-author Feng Ren, “broke new scientific ground” in predicting the composition of human proteins.
We at Insilico Medicine recognised that as a fantastic opportunity to use these structures in combination with our end-to-end AI platform to develop innovative therapies to treat serious unmet medical needs. The specialists from BC Cancer and the University of British Columbia demonstrated how well AI predicted the survival rates of cancer patients in another study journal.
More than 47,000 patients’ survival rates from six months to three and five years were examined.
According to Dr. John-Jose Nunez, the study’s primary author, “the AI basically reads the consultation document similarly to how a human would read it.”
The patient’s age, the type of cancer they have, any underlying diseases, any drug use in the past, and information about their relatives are all included in these documents. He urged that the AI compiles all the data to provide a more comprehensive picture of patient outcomes.
Despite this, researchers are just beginning to explore AI’s full potential in health care, including the detection and treatment of diseases. Nevertheless, studies indicate that it has the potential to be promising.
In order to provide patients with the best results, Nunez stated, “our hope is that a tool like this could be used to personalise and optimise the care they receive immediately.”